Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2017 (2017), Article ID 1864578, 19 pages
https://doi.org/10.1155/2017/1864578
Research Article

NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib

1Division of Science, School of Science Engineering and Technology, Abertay University, Dundee DD1 1HG, UK
2Cancer Research UK Edinburgh Centre and Division of Pathology Laboratory, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XU, UK
3Division of Computing and Mathematics, School of Design and Informatics, Abertay University, Dundee DD1 1HG, UK

Correspondence should be addressed to Yusuf Y. Deeni; ku.ca.yatreba@ineed.y

Received 6 May 2017; Revised 9 September 2017; Accepted 16 October 2017; Published 19 December 2017

Academic Editor: Javier Egea

Copyright © 2017 Ibrahim H. Kankia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Namani, Y. Li, X. J. Wang, and X. Tang, “Modulation of NRF2 signaling pathway by nuclear receptors: implications for cancer,” Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol. 1843, no. 9, pp. 1875–1885, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Tsuchida, T. Tsujita, M. Hayashi et al., “Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation,” Free Radical Biology and Medicine, vol. 103, pp. 236–247, 2017. View at Publisher · View at Google Scholar
  3. Y. Yarden, “The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities,” European Journal of Cancer, vol. 37, Supplement 4, pp. 3–8, 2001. View at Publisher · View at Google Scholar
  4. N. Normanno, A. De Luca, C. Bianco et al., “Epidermal growth factor receptor (EGFR) signaling in cancer,” Gene, vol. 366, no. 1, pp. 2–16, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Yarden and M. X. Sliwkowski, “Untangling the ErbB signalling network,” Nature Reviews Molecular Cell Biology, vol. 2, no. 2, pp. 127–137, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Gschwind, O. M. Fischer, and A. Ullrich, “The discovery of receptor tyrosine kinases: targets for cancer therapy,” Nature Reviews Cancer, vol. 4, no. 5, pp. 361–370, 2004. View at Publisher · View at Google Scholar
  7. C. A. Ritter and C. L. Arteaga, “The epidermal growth factor receptor–tyrosine kinase: a promising therapeutic target in solid tumors,” Seminars in Oncology, vol. 30, supplement 1, no. 1, pp. 3–11, 2003. View at Publisher · View at Google Scholar
  8. M. D. Marmor, K. B. Skaria, and Y. Yarden, “Signal transduction and oncogenesis by ErbB/HER receptors,” International Journal of Radiation Oncology Biology Physics, vol. 58, no. 3, pp. 903–913, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Bianco, D. Melisi, F. Ciardiello, and G. Tortora, “Key cancer cell signal transduction pathways as therapeutic targets,” European Journal of Cancer, vol. 42, no. 3, pp. 290–294, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. M. L. Friedlander, “Prognostic factors in ovarian cancer,” Seminars in Oncology, vol. 25, no. 3, pp. 305–314, 1998. View at Google Scholar
  11. A. Psyrri, M. Kassar, Z. Yu et al., “Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer,” Clinical Cancer Research, vol. 11, no. 24, pp. 8637–8643, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. S. L. Bull Phelps, J. O. Schorge, M. J. Peyton et al., “Implications of EGFR inhibition in ovarian cancer cell proliferation,” Gynecologic Oncology, vol. 109, no. 3, pp. 411–417, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. J. A. Ledermann and F. A. Raja, “Targeted trials in ovarian cancer,” Gynecologic Oncology, vol. 109, no. 1, pp. 151–156, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Alečković and Y. Kang, “Regulation of cancer metastasis by cell-free miRNAs,” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol. 1855, no. 1, pp. 24–42, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. A. J. Clayton, S. Danson, S. Jolly et al., “Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer,” British Journal of Cancer, vol. 91, no. 4, pp. 639–643, 2004. View at Publisher · View at Google Scholar
  16. C. D. Hough, C. A. Sherman-Baust, E. S. Pizer et al., “Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer,” Cancer Research, vol. 60, no. 22, pp. 6281–6287, 2000. View at Google Scholar
  17. J. D. Hayes and M. McMahon, “NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer,” Trends in Biochemical Sciences, vol. 34, no. 4, pp. 176–188, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. J. D. Hayes and M. L. J. Ashford, “Nrf2 orchestrates fuel partitioning for cell proliferation,” Cell Metabolism, vol. 16, no. 2, pp. 139–141, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. A. J. Hayes, C. Skouras, B. Haugk, and R. M. Charnley, “Keap1–Nrf2 signalling in pancreatic cancer,” The International Journal of Biochemistry & Cell Biology, vol. 65, pp. 288–299, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. X. J. Wang, J. D. Hayes, C. J. Henderson, and C. R. Wolf, “Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 49, pp. 19589–19594, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. X. Tang, H. Wang, L. Fan et al., “Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs,” Free Radical Biology and Medicine, vol. 50, no. 11, pp. 1599–1609, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. H. S. Khalil, S. P. Langdon, I. H. Kankia, J. Bown, and Y. Y. Deeni, “NRF2 regulates HER2 and HER3 signaling pathway to modulate sensitivity to targeted immunotherapies,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 4148791, 22 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Goltsov, Y. Deeni, H. S. Khalil et al., “Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy,” Cell, vol. 3, no. 2, pp. 563–591, 2014. View at Publisher · View at Google Scholar
  24. H. S. Khalil, S. P. Langdon, A. Goltsov et al., “A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells,” Oncotarget, vol. 7, no. 46, pp. 75874–75901, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. S. P. Langdon, S. S. Lawrie, F. G. Hay et al., “Characterization and properties of nine human ovarian adenocarcinoma cell lines,” Cancer Research, vol. 48, no. 21, pp. 6166–6172, 1988. View at Google Scholar
  26. S. P. Langdon, D. Faratian, Y. Nagumo, P. Mullen, and D. J. Harrison, “Pertuzumab for the treatment of ovarian cancer,” Expert Opinion on Biological Therapy, vol. 10, no. 7, pp. 1113–1120, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. S. P. Langdon and D. A. Cameron, “Pertuzumab for the treatment of metastatic breast cancer,” Expert Review of Anticancer Therapy, vol. 13, no. 8, pp. 907–918, 2013. View at Google Scholar
  28. P. Mullen, D. A. Cameron, M. Hasmann, J. F. Smyth, and S. P. Langdon, “Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signalling,” Molecular Cancer Therapeutics, vol. 6, no. 1, pp. 93–100, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. S. H. Tu, C. T. Ho, M. F. Liu et al., “Luteolin sensitises drug-resistant human breast cancer cells to tamoxifen via the inhibition of cyclin E2 expression,” Food Chemistry, vol. 141, no. 2, pp. 1553–1561, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. W. A. Messersmith and D. J. Ahnen, “Targeting EGFR in colorectal cancer,” The New England Journal of Medicine, vol. 359, no. 17, pp. 1834–1836, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. J. G. Paez, P. A. Jänne, J. C. Lee et al., “EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy,” Science, vol. 304, no. 5676, pp. 1497–1500, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Regales, Y. Gong, R. Shen et al., “Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer,” Journal of Clinical Investigation, vol. 119, no. 10, pp. 3000–3010, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. S. M. U. Ahmed, L. Luo, A. Namani, X. J. Wang, and X. Tang, “Nrf2 signaling pathway: pivotal roles in inflammation,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1863, no. 2, pp. 585–597, 2017. View at Publisher · View at Google Scholar
  34. A. Granata, R. Nicoletti, P. Perego et al., “Global metabolic profile identifies choline kinase alpha as a key regulator of glutathione-dependent antioxidant cell defense in ovarian carcinoma,” Oncotarget, vol. 6, no. 13, pp. 11216–11230, 2015. View at Publisher · View at Google Scholar
  35. A. Sandelin, W. W. Wasserman, and B. Lenhard, “ConSite: web-based prediction of regulatory elements using cross-species comparison,” Nucleic Acids Research, vol. 32, no. Web Server, pp. W249–W252, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Wang, Y. Chen, P. Sternberg, and J. Cai, “Essential roles of the PI3 kinase/Akt pathway in regulating Nrf2-dependent antioxidant functions in the RPE,” Investigative Ophthalmology and Visual Science, vol. 49, no. 4, pp. 1671–1678, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. H. K. Bryan, A. Olayanju, C. E. Goldring, and B. K. Park, “The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation,” Biochemical Pharmacology, vol. 85, no. 6, pp. 705–717, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. N. M. Reddy, H. R. Potteti, S. Vegiraju, H.-J. Chen, C. M. Tamatam, and S. P. Reddy, “PI3K-AKT signaling via Nrf2 protects against hyperoxia-induced acute lung injury, but promotes inflammation post-injury independent of Nrf2 in mice,” PLoS One, vol. 10, no. 6, article e0129676, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Wu, H. Wang, and X. Tang, “Rexinoid inhibits Nrf2-mediated transcription through retinoid X receptor alpha,” Biochemical and Biophysical Research Communications, vol. 452, no. 3, pp. 554–559, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. H. J. Forman, M. Maiorino, and F. Ursini, “Signaling functions of reactive oxygen species,” Biochemistry, vol. 49, no. 5, pp. 835–842, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. R. Mittler, S. Vanderauwera, N. Suzuki et al., “ROS signaling: the new wave?” Trends in Plant Science, vol. 16, no. 6, pp. 300–309, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Nordberg and E. S. J. Arnér, “Reactive oxygen species, antioxidants, and the mammalian thioredoxin system,” Free Radical Biology and Medicine, vol. 31, no. 11, pp. 1287–1312, 2011. View at Google Scholar
  43. H. Sies, V. S. Sharov, L. O. Klotz, and K. Briviba, “Glutathione peroxidase protects against peroxynitrite-mediated oxidations a new function for selenoproteins as peroxynitrite reductase,” Journal of Biological Chemistry, vol. 272, no. 44, pp. 27812–27817, 1997. View at Publisher · View at Google Scholar · View at Scopus
  44. A. K. Jaiswal, “Nrf2 signaling in coordinated activation of antioxidant gene expression,” Free Radical Biology and Medicine, vol. 36, no. 10, pp. 1199–1207, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Cao, S. Lu, A. Sowa et al., “Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs,” Cancer Letters, vol. 266, no. 2, pp. 249–262, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. D. M. Gu, P. H. Lu, K. Zhang et al., “EGFR mediates astragaloside IV-induced Nrf2 activation to protect cortical neurons against in vitro ischemia/reperfusion damages,” Biochemical and Biophysical Research Communications, vol. 457, no. 3, pp. 391–397, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Gui and K. Shen, “The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer,” Cancer Epidemiology, vol. 36, no. 5, pp. 490–496, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. H. S. Khalil, A. Goltsov, S. P. Langdon, D. J. Harrison, J. Bown, and Y. Deeni, “Quantitative analysis of NRF2 pathway reveals key elements of the regulatory circuits underlying antioxidant response and proliferation of ovarian cancer cells,” Journal of Biotechnology, vol. 202, pp. 12–30, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. M. McMahon, K. H. Campbell, A. K. MacLeod, L. A. McLaughlin, C. J. Henderson, and C. R. Wolf, “HDAC inhibitors increase NRF2-signaling in tumour cells and blunt the efficacy of co-adminstered cytotoxic agents,” PLoS One, vol. 9, no. 11, article e114055, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. B. Wang, X. Zhu, Y. Kim et al., “Histone deacetylase inhibition activates transcription factor Nrf2 and protects against cerebral ischemic damage,” Free Radical Biology and Medicine, vol. 52, no. 5, pp. 928–936, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. J. T. Garrett, M. G. Olivares, C. Rinehart et al., “Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase,” Proceedings of the National Academy of Sciences, vol. 108, no. 12, pp. 5021–5026, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. L. M. Zipper and R. T. Mulcahy, “Inhibition of ERK and p38 MAP kinases inhibits binding of Nrf2 and induction of GCS genes,” Biochemical and Biophysical Research Communications, vol. 278, no. 2, pp. 484–492, 2000. View at Publisher · View at Google Scholar · View at Scopus
  53. K. W. Kang, J. H. Ryu, and S. G. Kim, “The essential role of phosphatidylinositol 3-kinase and of p38 mitogen-activated protein kinase activation in the antioxidant response element-mediated rGSTA2 induction by decreased glutathione in H4IIE hepatoma cells,” Molecular Pharmacology, vol. 58, no. 5, pp. 1017–1025, 2000. View at Google Scholar
  54. M. Aslan and T. Özben, “Oxidants in receptor tyrosine kinase signal transduction pathways,” Antioxidants and Redox Signaling, vol. 5, no. 6, pp. 781–788, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Nguyen, P. Nioi, and C. B. Pickett, “The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress,” Journal of Biological Chemistry, vol. 284, no. 20, pp. 13291–13295, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. S. Hoelder, P. A. Clarke, and P. Workman, “Discovery of small molecule cancer drugs: successes, challenges and opportunities,” Molecular Oncology, vol. 6, no. 2, pp. 155–176, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. S. W. Brady, J. Zhang, D. Seok, H. Wang, and D. Yu, “Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor,” Molecular Cancer Therapeutics, vol. 13, no. 1, pp. 60–70, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. S. V. Karakashev and M. J. Reginato, “Hypoxia/HIF1 induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2,” Oncotarget, vol. 6, no. 4, pp. 1967–1980, 2015. View at Publisher · View at Google Scholar
  59. A. El Guerrab, M. Bamdad, Y. J. Bignon, F. Penault-Llorca, and C. Aubel, “Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells,” Molecular Carcinogenesis, vol. 56, no. 5, pp. 1383–1394, 2017. View at Google Scholar
  60. M. Scrima, F. Zito Marino, and D. M. Oliveira, “Aberrant signaling through the HER2-ERK1/2 pathway is predictive of reduced disease-free and overall survival in early stage non-small cell lung cancer (NSCLC) patients,” Journal of Cancer, vol. 8, no. 2, pp. 227–239, 2017. View at Publisher · View at Google Scholar
  61. T. Nakagawa, S. Takeuchi, T. Yamada et al., “Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer,” Molecular Cancer Therapeutics, vol. 11, no. 10, pp. 2149–2157, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. C. K. Lee, Y. L. Wu, P. N. Ding et al., “Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis,” Journal of Clinical Oncology, vol. 33, no. 17, pp. 1958–1965, 2015. View at Publisher · View at Google Scholar · View at Scopus
  63. R. Rosell, E. Carcereny, R. Gervais et al., “Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial,” Lancet Oncology, vol. 13, no. 3, pp. 239–246, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. W. K. Jeon, H. Y. Hong, and B. C. Kim, “Genipin up-regulates heme oxygenase-1 via PI3-kinase-JNK1/2-Nrf2 signaling pathway to enhance the anti-inflammatory capacity in RAW264.7 macrophages,” Archives of Biochemistry and Biophysics, vol. 512, no. 2, pp. 119–125, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. K. J. Rodriguez, H. K. Wong, T. Oddos, M. Southall, B. Frei, and S. Kaur, “A purified feverfew extract protects from oxidative damage by inducing DNA repair in skin cells via a PI3-kinase-dependent Nrf2/ARE pathway,” Journal of Dermatological Science, vol. 72, no. 3, pp. 304–310, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. K. P. Tan, K. Kosuge, M. Yang, and S. Ito, “NRF2 as a determinant of cellular resistance in retinoic acid cytotoxicity,” Free Radical Biology and Medicine, vol. 45, no. 12, pp. 1663–1673, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. E. Garattini, M. Bolis, S. K. Garattini et al., “Retinoids and breast cancer: from basic studies to the clinic and back again,” Cancer Treatment Reviews, vol. 40, no. 6, pp. 739–749, 2014. View at Publisher · View at Google Scholar · View at Scopus
  68. N. P. Mongan and L. J. Gudas, “Diverse actions of retinoid receptors in cancer prevention and treatment,” Differentiation, vol. 75, no. 9, pp. 853–870, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. C. Assaf, M. Bagot, R. Dummer et al., “Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion,” British Journal of Dermatology, vol. 155, no. 2, pp. 261–266, 2006. View at Publisher · View at Google Scholar · View at Scopus
  70. J. J. Scarisbrick, S. Morris, R. Azurdia et al., “UK consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma,” British Journal of Dermatology, vol. 168, no. 1, pp. 192–200, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. S. S. Gayle, S. L. Arnold, R. M. O'Regan, and R. Nahta, “Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance,” Anti-Cancer Agents in Medicinal Chemistry, vol. 12, no. 2, pp. 151–162, 2012. View at Publisher · View at Google Scholar
  72. N. A. O'Brien, K. McDonald, L. Tong et al., “Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT,” Clinical Cancer Research, vol. 20, no. 13, pp. 3507–3520, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. K. A. Whelan, L. P. Schwab, S. V. Karakashev et al., “The oncogene HER2/neu (ERBB2) requires the hypoxia-inducible factor HIF-1 for mammary tumor growth and anoikis resistance,” Journal of Biological Chemistry, vol. 288, no. 22, pp. 15865–15877, 2013. View at Publisher · View at Google Scholar · View at Scopus
  74. D. Malhotra, E. Portales-Casamar, A. Singh et al., “Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis,” Nucleic Acids Research, vol. 38, no. 17, pp. 5718–5734, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. Y. Hirotsu, F. Katsuoka, R. Funayama et al., “Nrf2–MafG heterodimers contribute globally to antioxidant and metabolic networks,” Nucleic Acids Research, vol. 40, no. 20, pp. 10228–10239, 2012. View at Publisher · View at Google Scholar · View at Scopus